ANKRD13B: A Potential Drug Target and Biomarker (G124930)

Target Name: ANKRD13B

NCBI ID: G124930

ANKRD13B

Other Name(s): Ankyrin repeat domain-containing protein 13B | Ankyrin repeat domain 13B | ankyrin repeat domain 13B | AN13B_HUMAN | FLJ25555

ANKRD13B: A Potential Drug Target and Biomarker

Introduction

Ankyrin repeat domains are a class of transmembrane proteins that contain a characteristic repeat sequence. They play an important role in cell biology and participate in many important biological processes. However, abnormal ankyrin repeat expression levels are associated with many diseases, including nervous system, cardiovascular diseases, tumors, etc. Therefore, in-depth study of the ankyrin repeat domain is of great significance for understanding the pathogenesis of these diseases. In this article, we introduce ANKRD13B, a protein with significant potential as a drug target or biomarker.

Overview of ANKRD13B

ANKRD13B is a protein that belongs to chromatin-binding proteins, and its encoding gene is NM_002116.1. It is a protein consisting of a single polypeptide chain with a molecular weight of 40 kDa. ANKRD13B is located in the cytoplasmic membrane of cells, mainly in the cytoplasm.

Structure of ANKRD13B

ANKRD13B has a unique secondary structure. It consists of two major subdomains: N-terminal 伪-helix and C-terminal 尾-coil. In addition, it also contains a special structural domain, called the middle domain, between the N-terminus and the C-terminus. This domain is composed of a complex 尾-turn and is closely related to the biological activity of the protein.

Functions of ANKRD13B

ANKRD13B plays an important role in many biological processes. It forms a barrier on the cell membrane, preventing certain substances from passing through the cell membrane, thereby maintaining the stability of the intracellular environment. In the nervous system, ANKRD13B is involved in many important signaling processes, including neuronal proliferation and apoptosis. In cardiovascular diseases, ANKRD13B is closely related to the interaction with receptors on the cell membrane, therefore, it may be related to the occurrence and development of cardiovascular diseases.

The relationship between abnormal expression of ANKRD13B and diseases

Many studies have shown that abnormal ANKRD13B expression is associated with many diseases. For example, neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, are associated with abnormal ANKRD13B expression. In addition, abnormal expression levels of ANKRD13B are also related to the occurrence of many tumors.

Pharmacological significance of ANKRD13B

Since ANKRD13B plays an important role in many biological processes, it is of high pharmacological significance. Many researchers are exploring ANKRD13B as a drug target or biomarker to treat various diseases. For example, some researchers are studying combination treatments using anti-neurodegenerative drugs to improve treatment effectiveness.

in conclusion

ANKRD13B is a protein that plays an important role in many biological processes. Aberrant ANKRD13B expression is associated with many diseases and, therefore, it is of high pharmacological significance. Future research will focus on better understanding the role of ANKRD13B in disease occurrence and development and developing new drugs to treat various diseases.

Protein Name: Ankyrin Repeat Domain 13B

Functions: Ubiquitin-binding protein that specifically recognizes and binds 'Lys-63'-linked ubiquitin. Does not bind 'Lys-48'-linked ubiquitin. Positively regulates the internalization of ligand-activated EGFR by binding to the Ub moiety of ubiquitinated EGFR at the cell membrane

The "ANKRD13B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD13B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets